{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Abnormal troponin I (cTnI)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Allergic reaction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Bilirubin increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Cardiac ischemia/infarction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Creatinine increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Diarrhea without colostomy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Duodenal ulcer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Fatigue/malaise/lethargy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Febrile neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"GI-other"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemolysis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Incontinence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Infection with 3-4 neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Infection, unk ANC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":"Leukopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Melena/ GI bleeding"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}],"title":"Neutropenia/granulocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"SGPT (ALT) increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Ureteral obstruction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Urinary tr infect w/ neutrop"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Urinary tr infect w/o neutrop"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Vomiting"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 2.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.","groups":[{"description":"Patients receive 3 cycles (1 cycle = 21 days) of neoadjuvant chemotherapy (800 mg/m\\^2 of gemcitabine IV and 80 mg/m\\^2 of Paclitaxel IV on days 1 and 8 and Carboplatin IV on day 1), TURBT within 4-8 weeks of chemotherapy, option of proceeding with immediate cystectomy or observation.","id":"OG000","title":"Gemcitabine, Paclitaxel, Carboplatin Followed by Surgery"}],"paramType":"NUMBER","populationDescription":"Eligible patients who had received any treatment were included in the adverse event summaries. Any CTCAE 3.0 event of Grade 3 (severe), Grade 4 (life threatening), or Grade 5 (fatal) which deemed to be related to protocol treatment are included.","reportingStatus":"POSTED","timeFrame":"Patients were assessed for adverse events at weeks 1, 2, 4, 5, 7, 8, and following surgery","title":"Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","type":"SECONDARY","unitOfMeasure":"Participants"}